for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CTI BioPharma Corp

CTIC.O

Latest Trade

1.05USD

Change

0.00(0.00%)

Volume

84,453

Today's Range

1.02

 - 

1.06

52 Week Range

0.62

 - 

1.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.05
Open
1.04
Volume
84,453
3M AVG Volume
14.44
Today's High
1.06
Today's Low
1.02
52 Week High
1.95
52 Week Low
0.62
Shares Out (MIL)
73.72
Market Cap (MIL)
75.93
Forward P/E
-1.76
Dividend (Yield %)
--

Next Event

CTI Biopharma Corp Annual Shareholders Meeting

Latest Developments

More

CTI Biopharma Reports Second Quarter 2020 Financial Results

Cti Biopharma Reports First Quarter 2020 Financial Results

Cti Biopharma Reports Fourth Quarter And Full Year 2019 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CTI BioPharma Corp

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Industry

Biotechnology & Drugs

Contact Info

3101 Western Ave Ste 800

SEATTLE, WA

98121-3017

United States

+1.206.2827100

http://www.ctibiopharma.com/

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-1.240

2018

-0.520

2019

-0.690

2020(E)

-0.697
Price To Earnings (TTM)
--
Price To Sales (TTM)
33.17
Price To Book (MRQ)
1.34
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
12.07
LT Debt To Equity (MRQ)
3.60
Return on Investment (TTM)
-76.13
Return on Equity (TTM)
-62.27

Latest News

Latest News

BRIEF-Cti Biopharma Reports Q1 EPS Loss Per Share Of $0.08

* AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENTS TOTALED $104.6 MILLION, COMPARED TO $43.2 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

BRIEF-Children's Hospital Of Philadelphia Foundation To Engage In Dialogue With Spark Therapeutics To Be Allowed To Designate At Least 1 Board Member

* CHILDREN'S HOSPITAL OF PHILADELPHIA FOUNDATION - TO ENGAGE IN DIALOGUE WITH SPARK THERAPEUTICS TO BE ALLOWED TO DESIGNATE AT LEAST 1 BOARD MEMBER

BRIEF-CTI Biopharma Q4 Loss Per Share $0.33

* CTI BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Tempest Therapeutics Inc Says It Has Raised $25.2 Million In Equity Financing

* TEMPEST THERAPEUTICS, INC FILES TO SAY IT HAS RAISED $25.2 MILLION IN EQUITY FINANCING - SEC FILING

BRIEF-Growth Equity Opportunities Fund Reports 6.0 Pct Stake In CTI Biopharma

* GROWTH EQUITY OPPORTUNITIES FUND V LLC REPORTS 6.0 PERCENT STAKE IN CTI BIOPHARMA CORP AS OF FEB 8 - SEC FILING

BRIEF-CTI BioPharma Prices Underwritten Public Offering Of $60 Million Of Common Stock

* CTI BIOPHARMA PRICES UNDERWRITTEN PUBLIC OFFERING OF $60 MILLION OF COMMON STOCK

BRIEF-CTI Biopharma Announces Launch Of Follow-On Offering

* CTI BIOPHARMA CORP - INTENDS TO USE NET PROCEEDS OF OFFERING TO COMPLETE PAC203 CLINICAL TRIAL, COMPLETE REVIEW OF PACRITINIB MAA BY EMA, AMONG OTHERS Source text for Eikon:

BRIEF-CTI Biopharma Provides Corporate And European Regulatory Update

* CTI BIOPHARMA PROVIDES CORPORATE AND EUROPEAN REGULATORY UPDATE

BRIEF-CTI BioPharma to receive $10 mln milestone payment for Trisenox

* CTI BIOPHARMA TO RECEIVE $10 MILLION MILESTONE PAYMENT FOR TRISENOX®

BRIEF-Spotlight Therapeutics Inc Says It Has Raised $7.3 Million In Equity Financing

* SPOTLIGHT THERAPEUTICS INC FILES TO SAY IT HAS RAISED $7.3 MILLION IN EQUITY FINANCING - SEC FILING

BRIEF-CTI Biopharma Corp Says Co Entered Into A Loan And Security Agreement​

* CTI BIOPHARMA CORP - ON NOVEMBER 28, 2017, CTI BIOPHARMA CORP ENTERED INTO A LOAN AND SECURITY AGREEMENT

BRIEF-CTI BIOPHARMA FILES FOR MIXED SHELF OF UP TO $200 MLN

* CTI BIOPHARMA CORP FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING Source text: (http://bit.ly/2zo6CPZ) Further company coverage:

BRIEF-CTI Biopharma reports third quarter 2017 financial results

* CTI Biopharma Corp - total revenues for q3 were $1.7 million compared to $4.4 million Source text for Eikon: Further company coverage:

BrainStorm enrolls first patients in advanced ALS stem cell trial

BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

BRIEF-CTI Biopharma appoints Laurent Fischer as new board chairman

* CTI Biopharma appoints Laurent Fischer as new chairman of the board and announces management promotions

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up